Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar 11;2015(3):CD010480.
doi: 10.1002/14651858.CD010480.pub2.

HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass

Michelle Lewicki  1 , Irene Ng, Antoine G Schneider
Affiliations
Review

HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass

Michelle Lewicki et al. Cochrane Database Syst Rev. .

Abstract

Background: Acute kidney injury (AKI) is common in patients undergoing cardiac surgery among whom it is associated with poor outcomes, prolonged hospital stays and increased mortality. Statin drugs can produce more than one effect independent of their lipid lowering effect, and may improve kidney injury through inhibition of postoperative inflammatory responses.

Objectives: This review aimed to look at the evidence supporting the benefits of perioperative statins for AKI prevention in hospitalised adults after surgery who require cardiac bypass. The main objectives were to 1) determine whether use of statins was associated with preventing AKI development; 2) determine whether use of statins was associated with reductions in in-hospital mortality; 3) determine whether use of statins was associated with reduced need for RRT; and 4) determine any adverse effects associated with the use of statins.

Search methods: We searched the Cochrane Renal Group's Specialised Register to 13 January 2015 through contact with the Trials' Search Co-ordinator using search terms relevant to this review.

Selection criteria: Randomised controlled trials (RCTs) that compared administration of statin therapy with placebo or standard clinical care in adult patients undergoing surgery requiring cardiopulmonary bypass and reporting AKI, serum creatinine (SCr) or need for renal replacement therapy (RRT) as an outcome were eligible for inclusion. All forms and dosages of statins in conjunction with any duration of pre-operative therapy were considered for inclusion in this review.

Data collection and analysis: All authors extracted data independently and assessments were cross-checked by a second author. Likewise, assessment of study risk of bias was initially conducted by one author and then by a second author to ensure accuracy. Disagreements were arbitrated among authors until consensus was reached. Authors from two of the included studies provided additional data surrounding post-operative SCr as well as need for RRT. Meta-analyses were used to assess the outcomes of AKI, SCr and mortality rate. Data for the outcomes of RRT and adverse effects were not pooled. Adverse effects taken into account were those reported by the authors of included studies.

Main results: We included seven studies (662 participants) in this review. All except one study was assessed as being at high risk of bias. Three studies assessed atorvastatin, three assessed simvastatin and one investigated rosuvastatin. All studies collected data during the immediate perioperative period only; data collection to hospital discharge and postoperative biochemical data collection ranged from 24 hours to 7 days. Overall, pre-operative statin treatment was not associated with a reduction in postoperative AKI, need for RRT, or mortality. Only two studies (195 participants) reported postoperative SCr level. In those studies, patients allocated to receive statins had lower postoperative SCr concentrations compared with those allocated to no drug treatment/placebo (MD 21.2 µmol/L, 95% CI -31.1 to -11.1). Adverse effects were adequately reported in only one study; no difference was found between the statin group compared to placebo.

Authors' conclusions: Analysis of currently available data did not suggest that preoperative statin use is associated with decreased incidence of AKI in adults after surgery who required cardiac bypass. Although a significant reduction in SCr was seen postoperatively in people treated with statins, this result was driven by results from a single study, where SCr was considered as a secondary outcome. The results of the meta-analysis should be interpreted with caution; few studies were included in subgroup analyses, and significant differences in methodology exist among the included studies. Large high quality RCTs are required to establish the safety and efficacy of statins to prevent AKI after cardiac surgery.

PubMed Disclaimer

Conflict of interest statement

  1. Michelle Lewicki: None known

  2. Irene Ng: None known

  3. Antoine G Schneider: None known

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1 Statins versus placebo/no treatment, Outcome 1 Acute kidney injury.
1.2
1.2. Analysis
Comparison 1 Statins versus placebo/no treatment, Outcome 2 Serum creatinine: 24 h postoperatively.
1.3
1.3. Analysis
Comparison 1 Statins versus placebo/no treatment, Outcome 3 Serum creatinine: 48 h postoperatively.
1.4
1.4. Analysis
Comparison 1 Statins versus placebo/no treatment, Outcome 4 Mortality.
1.5
1.5. Analysis
Comparison 1 Statins versus placebo/no treatment, Outcome 5 Renal replacement therapy.
1.6
1.6. Analysis
Comparison 1 Statins versus placebo/no treatment, Outcome 6 Adverse events.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD010480

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Almansob 2012 {published data only}
    1. Almansob MA, Xu B, Zhou L, Hu XX, Chen W, Chang FJ, et al. Simvastatin reduces myocardial injury undergoing noncoronary artery cardiac surgery: A randomized controlled trial. Arteriosclerosis Thrombosis & Vascular Biology 2012;32(9):2304‐13. [MEDLINE: ] - PubMed
Chello 2006 {published data only}
    1. Chello M, Patti G, Candura D, Mastrobuoni S, Sciascio G, Agro F, et al. Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Critical Care Medicine 2006;34(3):660‐7. [MEDLINE: ] - PubMed
Christenson 1999 {published data only}
    1. Christenson JT. Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease. American Journal of Cardiology 2001;88(8):896‐9. [MEDLINE: ] - PubMed
    1. Christenson JT. Preoperative lipid control with simvastatin reduces the risk for graft failure already 1 year after myocardial revascularization. Cardiovascular Surgery 2001;9(1):33‐43. [MEDLINE: ] - PubMed
    1. Christenson JT. Preoperative lipid‐control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. European Journal of Cardio‐Thoracic Surgery 1999;15(4):394‐9. [MEDLINE: ] - PubMed
Mannacio 2008 {published data only}
    1. Mannacio VA, Iorio D, Amicis V, Lello F, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. Journal of Thoracic & Cardiovascular Surgery 2008;136(6):1541‐8. [MEDLINE: ] - PubMed
Prowle 2012 {published data only}
    1. Prowle JR, Calzavacca P, Licari E, Ligabo EV, Echeverri JE, Haase M, et al. Pilot double‐blind, randomized controlled trial of short‐term atorvastatin for prevention of acute kidney injury after cardiac surgery. Nephrology 2012;17(3):215‐24. [MEDLINE: ] - PubMed
    1. Prowle JR, Licari E, Calzavacca P, Ligabo EV, Echeverri JE, Hasse M, et al. Peri‐operative statin therapy does not alter the incidence of acute kidney injury after cardiopulmonary bypass: CREAT, the cardiopulmonary bypass, renal injury and atorvastatin trial. clinicaltrials.gov NCT00910221 [abstract]. Intensive Care Medicine 2010;36:S88. [EMBASE: 70290230]
Spadaccio 2010 {published data only}
    1. Spadaccio C, Pollari F, Casacalenda A, Alfano G, Genovese J, Covino E, et al. Atorvastatin increases the number of endothelial progenitor cells after cardiac surgery: a randomized control study. Journal of Cardiovascular Pharmacology 2010;55(1):30‐8. [MEDLINE: ] - PubMed
Tamayo 2009 {published data only}
    1. Tamayo E, Alonso O, Alvarez FJ, Castrodeza J, Florez S, Stefano S. Effects of simvastatin on acute‐phase protein levels after cardiac surgery [Efecto de la simvastatina en la concentracion de las proteinas de fase aguda despues de la cirugia cardiaca]. Medicina Clinica 2008;130(20):773‐5. [MEDLINE: ] - PubMed
    1. Tamayo E, Alvarez FJ, Alonso O, Bustamente R, Castrodeza J, Soria S, et al. Effects of simvastatin on systemic inflammatory responses after cardiopulmonary bypass. Journal of Cardiovascular Surgery 2009;50(5):687‐94. [MEDLINE: ] - PubMed

References to studies excluded from this review

Acikel 2010 {published data only}
    1. Acikel S, Muderrisoglu H, Yildirir A, Aydinalp A, Sade E, Bayraktar N, et al. Prevention of contrast‐induced impairment of renal function by short‐term or long‐term statin therapy in patients undergoing elective coronary angiography. Blood Coagulation & Fibrinolysis 2010;21(8):750‐7. [MEDLINE: ] - PubMed
Almeida 2010 {published data only}
    1. Almeida R, Coelho OR, Meneses FH, Oliveira G, Molinari G, Franca R, et al. The APVS (atorvastatin in the perioperative of vascular surgery) study [abstract]. Circulation 2010;122(2):e345. [EMBASE: 70233157]
Antoniades 2010 {published data only}
    1. Antoniades C, Bakogiannis C, Tousoulis D, Reilly S, Zhang MH, Paschalis A, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH‐oxidase activity. Circulation 2010;122(11 Suppl):S66‐73. [MEDLINE: ] - PubMed
    1. Antoniades C, Bakogiannis C, Tousoulis D, Zhang MH, Demosthenous M, Antonopoulos A, et al. Preoperative atorvastatin treatment rapidly improves vein graft redox state by inhibiting rac1 and NADPH oxidase activity in patients undergoing elective CABG [abstract]. European Heart Journal 2010;31(Suppl 1):310. [EMBASE: 70280690] - PubMed
    1. Antoniades C, Demosthenous M, Margaritis M, Tousoulis D, Antonopoulos A, Paschalis A, et al. Short‐term preoperative treatment with atorvastatin improves myocardial redox state in patients undergoing elective CABG by affecting NADPH oxidase activity and NOS coupling [abstract]. European Heart Journal 2010;31(Suppl 1):60. [EMBASE: 70279719]
Antoniades 2010a {published data only}
    1. Antoniades CA, Paschalis A, Tousoulis D, Bakogiannis C, Dimosthenous M, Antonopoulos AS, et al. Atorvastatin rapidly modifies vascular redox and increases nitric oxide bioavailability in human arteries [abstract]. Journal of the American College of Cardiology 2010;55(10 Suppl 1):A123. [EMBASE: 70096347]
    1. Demosthenous M, Antoniades C, Paschalis A, Tousoulis D, Bakogiannis C, Antonopoulos AS, et al. Atorvastatin rapidly modifies vascular redox state and improves nitric oxide bioavailability in human vessels obtained from patients with advanced atherosclerosis [abstract]. European Heart Journal 2010;31(Suppl 1):1023. [EMBASE: 70283432]
ARMYDA‐CIN 2011 {published data only}
    1. Patti G, Ricottini E, Nusca A, Colonna G, Pasceri V, D'Ambrosio A, et al. Short‐term, high‐dose Atorvastatin pretreatment to prevent contrast‐induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA‐CIN [atorvastatin for reduction of myocardial damage during angioplasty‐‐contrast‐induced nephropathy] trial. American Journal of Cardiology 2011;108(1):1‐7. [MEDLINE: ] - PubMed
Barbir 1994 {published data only}
    1. Barbir M, Hunt BJ, Galloway D, Taylor A, Ilsley C, Mitchell A, et al. A randomized pilot trial of low‐dose combination lipid‐lowering therapy following coronary artery bypass grafting. Clinical Cardiology 1994;17(2):59‐64. [MEDLINE: ] - PubMed
Berkan 2009 {published data only}
    1. Berkan O, Katrancioglu N, Ozker E, Ozerdem G, Bakici Z, Yilmaz MB. Reduced P‐selectin in hearts pretreated with fluvastatin: a novel benefit for patients undergoing open heart surgery. Thoracic & Cardiovascular Surgeon 2009;57(2):91‐5. [MEDLINE: ] - PubMed
Caorsi 2008 {published data only}
    1. Caorsi C, Pineda F, Munoz C. Pravastatin immunomodulates IL‐6 and C‐reactive protein, but not IL‐1 and TNF‐alpha, in cardio‐pulmonary bypass. European Cytokine Network 2008;19(2):99‐103. [MEDLINE: ] - PubMed
Chello 2003 {published data only}
    1. Chello M, Mastroroberto P, Patti G, D'Ambrosio A, Morichetti MC, Sciascio G, et al. Simvastatin attenuates leucocyte‐endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart 2003;89(5):538‐43. [MEDLINE: ] - PMC - PubMed
Chello 2005 {published data only}
    1. Chello M, Goffredo C, Patti G, Candura D, Melfi R, Mastrobuoni S, et al. Effects of atorvastatin on arterial endothelial function in coronary bypass surgery. European Journal of Cardio‐Thoracic Surgery 2005;28(6):805‐10. [MEDLINE: ] - PubMed
Chello 2007 {published data only}
    1. Chello M, Anselmi A, Spadaccio C, Patti G, Goffredo C, Sciascio G, et al. Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery. Annals of Thoracic Surgery 2007;83(4):1374‐80. [MEDLINE: ] - PubMed
Chen 2009a {published data only}
    1. Chen GL, Su JZ. Atorvastatin attenuated contrast induced renal function damage. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2009;37(5):389‐93. [MEDLINE: ] - PubMed
Cobbaert 1992 {published data only}
    1. Cobbaert C, Sergeant P, Meyns B, Szecsi J, Kesteloot H. Time course of serum Lp(a) in men after coronary artery bypass grafting. Acta Cardiologica 1992;47(6):529‐42. [MEDLINE: ] - PubMed
Coccia 2007 {published data only}
    1. Coccia R, Spadaccio C, Foppoli C, Perluigi M, Covino E, Lusini M, et al. The effect of simvastatin on erythrocyte membrane fluidity during oxidative stress induced by cardiopulmonary bypass: a randomized controlled study. Clinical Therapeutics 2007;29(8):1706‐17. [MEDLINE: ] - PubMed
Dotani 2003 {published data only}
    1. Dotani MI, Morise AP, Haque R, Jain AC, Gupta N, Gibson CM. Association between short‐term simvastatin therapy before coronary artery bypass grafting and postoperative myocardial blood flow as assessed by positron emission tomography. American Journal of Cardiology 2003;91(9):1107‐9. [MEDLINE: ] - PubMed
Dunkelgrun 2009 {published data only}
    1. Dunkelgrun M, Boersma E, Schouten O, Koopman‐van Gemert AW, Poorten F, Bax JJ, et al. Bisoprolol and fluvastatin for the reduction of perioperative cardiac mortality and myocardial infarction in intermediate‐risk patients undergoing noncardiovascular surgery: a randomized controlled trial (DECREASE‐IV). Annals of Surgery 2009;249(6):921‐6. [MEDLINE: ] - PubMed
Durazzo 2004 {published data only}
    1. Caramelli B, Durazzo A, Ikeoka D, Bernoche C, Monachini M, Puech Leao P, et al. Short‐term treatment with atorvastatin for prevention of cardiac complications after vascular surgery [abstract no: 086]. Atherosclerosis Supplements 2002;3(2):83. [CENTRAL: CN‐00831428]
    1. Durazzo AE, Machado FS, Ikeoka DT, Bernoche C, Monachini MC, Puech‐Leao P, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. Journal of Vascular Surgery 2004;39(5):967‐75. [MEDLINE: ] - PubMed
Faulkner 2000 {published data only}
    1. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid‐lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. Pharmacotherapy: The Journal of Human Pharmacology & Drug Therapy 2000;20(4):410‐6. [MEDLINE: ] - PubMed
Flaker 1999 {published data only}
    1. Flaker GC, Warnica JW, Sacks FM, Moye LA, Davis BR, Rouleau JL, et al. Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. Journal of the American College of Cardiology 1999;34(1):106‐12. [MEDLINE: ] - PubMed
FLARE Study 1999 {published data only}
    1. Lloyd GW, Jackson G, Foley DP, Boersma E, Shepherd J, Serruys PW. The influence of plasma lipoprotein (a) on angiographic restenosis and coronary events in patients undergoing planned coronary balloon angioplasty. Ancillary analysis of the Fluvastatin Angioplasty Restenosis (FLARE) trial. Atherosclerosis 2001;158(2):445‐54. [MEDLINE: ] - PubMed
    1. Serruys PW, Foley DP, Jackson G, Bonnier H, Macaya C, Vrolix M, et al. A randomized placebo‐controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. European Heart Journal 1999;20(1):58‐69. [MEDLINE: ] - PubMed
Florens 2001 {published data only}
    1. Florens E, Salvi S, Peynet J, Elbim C, Mallat Z, Bel A, et al. Can statins reduce the inflammatory response to cardiopulmonary bypass? A clinical study. Journal of Cardiac Surgery 2001;16(3):232‐9. [MEDLINE: ] - PubMed
Foley 1994 {published data only}
    1. Foley DP, Bonnier H, Jackson G, Macaya C, Shepherd J, Vrolix M, et al. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group. American Journal of Cardiology 1994;73(14):50D‐61D. [MEDLINE: ] - PubMed
Han 2014 {published data only}
    1. Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, et al. Short‐term rosuvastatin therapy for prevention of contrast‐induced acute kidney injury in patients with diabetes and chronic kidney disease. Journal of the American College of Cardiology 2014;63(1):62‐70. [MEDLINE: ] - PubMed
Ji 2009 {published data only}
    1. Ji Q, Mei Y, Wang X, Sun Y, Feng J, Cai J, et al. Effect of preoperative atorvastatin therapy on atrial fibrillation following off‐pump coronary artery bypass grafting. Circulation Journal 2009;73(12):2244‐9. [MEDLINE: ] - PubMed
Kesteloot 1992 {published data only}
    1. Kesteloot H, Cobbaert C, Meyns B, Szecsi J, Lesaffre E, Sergeant P. Time course of serum lipid and lipoprotein levels after coronary bypass surgery: modification by pravastatin. Acta Cardiologica 1992;47(6):519‐28. [MEDLINE: ] - PubMed
Kourliouros 2011 {published data only}
    1. Kourliouros A, Valencia O, Hosseini MT, Mayr M, Sarsam M, Camm J, et al. Preoperative high‐dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. Journal of Thoracic & Cardiovascular Surgery 2011;141(1):244‐8. [MEDLINE: ] - PubMed
Krivoy 2008 {published data only}
    1. Krivoy N, Adler Z, Saloma R, Hawadie A, Azzam ZS. Targeting C‐reactive protein levels using high‐dose atorvastatin before coronary artery bypass graft surgery. Experimental & Clinical Cardiology 2008;13(4):171‐4. [EMBASE: 2009154149] - PMC - PubMed
Li 2012a {published data only}
    1. Li W, Fu X, Wang Y, Li X, Yang Z, Wang X, et al. Beneficial effects of high‐dose atorvastatin pretreatment on renal function in patients with acute ST‐segment elevation myocardial infarction undergoing emergency percutaneous coronary intervention. Cardiology 2012;122(3):195‐202. [MEDLINE: ] - PubMed
LIPS Study 2002 {published data only}
    1. Arampatzis CA, Goedhart D, Serruys PW, Saia F, Lemos PA, Feyter P, et al. Fluvastatin reduces the impact of diabetes on long‐term outcome after coronary intervention‐‐a Lescol Intervention Prevention Study (LIPS) substudy. American Heart Journal 2005;149(2):329‐35. [MEDLINE: ] - PubMed
    1. Serruys PW, Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002;287(24):3215‐22. [MEDLINE: ] - PubMed
Lotfi 2008 {published data only}
    1. Lotfi A, Schweiger MJ, Giugliano GR, Murphy SA, Cannon CP, TIMI 22 Investigators. High‐dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients‐‐a Pravastatin or Atorvastatin Evaluation and Infection Therapy‐Thrombolysis in Myocardial Infarction 22 (PROVE IT‐TIMI 22) analysis. American Heart Journal 2008;155(5):954‐8. [MEDLINE: ] - PubMed
Ludman 2010 {published data only}
    1. Ludman AJ, Hausenloy DJ, Venugopal V, Babu G, Boston‐Griffiths E, Lawrence D, et al. The effect of high‐dose atorvastatin on a background of standard‐dose chronic statin therapy in patients undergoing cardiac surgery [abstract]. European Heart Journal 2010;31(Suppl 1):70. [EMBASE: 70279760]
Morawietz 2006 {published data only}
    1. Morawietz H, Erbs S, Holtz J, Schubert A, Krekler M, Goettsch W, et al. Endothelial Protection, AT1 blockade and Cholesterol‐Dependent Oxidative Stress: the EPAS trial. Circulation 2006;114(1 Suppl):1296‐301. [MEDLINE: ] - PubMed
Nakamura 2006b {published data only}
    1. Nakamura K, Masuda H, Kariyazono H, Arima J, Iguro Y, Yamada K, et al. Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting. Cytokine 2006;36(5‐6):201‐10. [MEDLINE: ] - PubMed
Ozhan 2010 {published data only}
    1. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short‐term high‐dose atorvastatin for prevention of contrast‐induced nephropathy in patients undergoing coronary angiography. Angiology 2010;61(7):711‐4. [MEDLINE: ] - PubMed
Post‐CABG Trial 1997 {published data only}
    1. Alaupovic P, Fesmire JD, Hunnighake D, Domanski M, Forman S, Knatterud GL, et al. The effect of aggressive and moderate lowering of LDL‐cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial. Atherosclerosis 1999;146(2):369‐79. [MEDLINE: ] - PubMed
    1. Campeau L, Lesperance J, Bilodeau L, Fortier A, Guertin MC, Knatterud GL. Effect of cholesterol lowering and cardiovascular risk factors on the progression of aortoiliac arteriosclerosis: a quantitative cineangiography study. Angiology 2005;56(2):191‐9. [MEDLINE: ] - PubMed
    1. Canner PL, Thompson B, Knatterud GL, Geller N, Campeau L, Zucker D. An application of the Zucker‐Wittes modified ratio estimate statistic in the Post Coronary Artery Bypass Graft (CABG) clinical trial. Controlled Clinical trials 1997;18(4):318‐27. [MEDLINE: ] - PubMed
    1. Domanski M, Tian X, Fleg J, Coady S, Gosen C, Kirby R, et al. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial. American Journal of Cardiology 2008;102(8):1023‐7. [MEDLINE: ] - PubMed
    1. Hunninghake DB. Therapeutic efficacy of the lipid‐lowering armamentarium: the clinical benefits of aggressive lipid‐lowering therapy. American Journal of Medicine 1998;104(2A):9S‐13S. [MEDLINE: ] - PubMed
PRATO‐ACS Study 2014 {published data only}
    1. Leoncini M, Toso A, Maioli M, Tropeano F, Villani S, Bellandi F. Early high‐dose rosuvastatin for contrast‐induced nephropathy prevention in acute coronary syndrome: Results from the PRATO‐ACS Study (Protective Effect of Rosuvastatin and Antiplatelet Therapy On contrast‐induced acute kidney injury and myocardial damage in patients with Acute Coronary Syndrome). Journal of the American College of Cardiology 2014;63(1):71‐9. [MEDLINE: ] - PubMed
PROMISS Study 2008 {published data only}
    1. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium‐induced nephropathy using short‐term high‐dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial‐‐a randomized controlled study. American Heart Journal 2008;155(3):499. [MEDLINE: ] - PubMed
Qian 2008 {published data only}
    1. Qian YJ, Xiao XJ, Yuan HS, Tang H, Shao HZ, Wei DM. Combination pharmacological cardioversion of permanent atrial fibrillation in post‐prosthetic mitral valve replacement outpatients: a novel approach for the treatment of atrial fibrillation. Journal of International Medical Research 2008;36(3):537‐43. [MEDLINE: ] - PubMed
Radaelli 2007 {published data only}
    1. Radaelli A, Loardi C, Cazzaniga M, Balestri G, DeCarlini C, Cerrito MG, et al. Inflammatory activation during coronary artery surgery and its dose‐dependent modulation by statin/ACE‐inhibitor combination. Arteriosclerosis, Thrombosis & Vascular Biology 2007;27(12):2750‐5. [MEDLINE: ] - PubMed
RAP Study 2010 {published data only}
    1. Billings FT 4th, Pretorius M, Siew ED, Yu C, Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. Journal of Cardiothoracic & Vascular Anesthesia 2010;24(6):913‐20. [MEDLINE: ] - PMC - PubMed
Riahi 2006 {published data only}
    1. Riahi S, Schmidt EB, Amanavicius N, Karmisholt J, Jensen HS, Christoffersen RP, et al. The effect of atorvastatin on heart rate variability and lipoproteins in patients treated with coronary bypass surgery. International Journal of Cardiology 2006;111(3):436‐41. [MEDLINE: ] - PubMed
Sasmazel 2010 {published data only}
    1. Sasmazel A, Baysal A, Fedekar A, Buyukbayrak F, Bugra O, Erdem H, et al. The effect of statin therapy on stimulation of endothelium‐derived nitric oxide before and after coronary artery bypass surgery. Heart Surgery Forum 2010;13(4):E243‐6. [MEDLINE: ] - PubMed
Schanzer 2008 {published data only}
    1. Schanzer A, Hevelone N, Owens CD, Beckman JA, Belkin M, Conte MS. Statins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia. Journal of Vascular Surgery 2008;47(4):774‐81. [MEDLINE: ] - PubMed
Schouten 2009 {published data only}
    1. Schouten O, Boersma E, Hoeks SE, Benner R, Urk H, Sambeek MR, et al. Fluvastatin and perioperative events in patients undergoing vascular surgery. New England Journal of Medicine 2009;361(10):980‐9. [MEDLINE: ] - PubMed
Song 2008 {published data only}
    1. Song YB, On YK, Kim JH, Shin DH, Kim JS, Sung J, et al. The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off‐pump coronary artery bypass grafting surgery. American Heart Journal 2008;156(2):373‐16. [MEDLINE: ] - PubMed
STATIN‐STEMI Study 2010 {published data only}
    1. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, et al. Efficacy of high‐dose atorvastatin loading before primary percutaneous coronary intervention in ST‐segment elevation myocardial infarction: the STATIN STEMI trial. [Erratum appears in JACC Cardiovasc Interv. 2012 Feb;5(2):248]. JACC: Cardiovascular Interventions 2010;3(3):332‐9. [MEDLINE: ] - PubMed
Su 2011 {published data only}
    1. Su JZ, Xue Y, Cai WQ, Huang QY, Chai DJ, Chen GL, et al. Association between high sensitivity C‐reactive protein and contrast induced acute kidney injury in patients with acute coronary syndrome undergoing percutaneous coronary intervention: impact of atorvastatin. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2011;39(9):807‐11. [MEDLINE: ] - PubMed
Sun 2009a {published data only}
    1. Sun YF, Mei YQ, Ji Q, Wang XS, Feng J, Cai JZ, et al. Effect of atorvastatin on postoperative atrial fibrillation in patients undergoing coronary artery bypass grafting. Chung‐Hua i Hsueh Tsa Chih [Chinese Medical Journal] 2009;89(42):2988‐91. [MEDLINE: ] - PubMed
Tetik 2010 {published data only}
    1. Tetik S, Ak K, Isbir S, Eksioglu‐Demiralp E, Arsan S, Iqbal O, et al. Clopidogrel provides significantly greater inhibition of platelet activity than aspirin when combined with atorvastatin after coronary artery bypass grafting: a prospective randomized study. Clinical & Applied Thrombosis/Hemostasis 2010;16(2):189‐98. [MEDLINE: ] - PubMed
Toso 2010 {published data only}
    1. Toso A, Leoncini M, Maioli M, Gallopin M, Tedeschi D, Amato M, et al. Short‐term high‐dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. Journal of Cardiovascular Medicine 2011;12(5):318‐21. [MEDLINE: ] - PubMed
    1. Toso A, Maioli M, Leoncini M, Gallopin M, Tedeschi D, Micheletti C, et al. Usefulness of atorvastatin (80 mg) in prevention of contrast‐induced nephropathy in patients with chronic renal disease. American Journal of Cardiology 2010;105(3):288‐92. [MEDLINE: ] - PubMed
Xinwei 2009 {published data only}
    1. Xinwei J, Xianghua F, Jing Z, Xinshun G, Ling X, Weize F, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast‐induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. American Journal of Cardiology 2009;104(4):519‐24. [MEDLINE: ] - PubMed
Zhou 2009 {published data only}
    1. Zhou X, Jin YZ, Wang Q, Min R, Zhang XY. Efficacy of high dose atorvastatin on preventing contrast induced nephropathy in patients underwent coronary angiography. Chung‐Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology] 2009;37(5):394‐6. [MEDLINE: ] - PubMed
Zhou 2010 {published data only}
    1. Zhou Q, Wang G, Gao C, Chen T. Effect of ulinastatin on perioperative inflammatory response to coronary artery bypass grafting with cardiopulmonary bypass. Zhong Nan da Xue Xue Bao. Yi Xue Ban [Journal of Central South University Medical Sciences] 2010;35(2):107‐10. [MEDLINE: ] - PubMed

References to studies awaiting assessment

de Oliveira 2012 {published data only}
    1. Oliveira MS, Martins KB, Costa JR Jr, Abizaid A, Stadler J, Mattos LA, et al. Impact on renal function of rosuvastatin preload prior to elective percutaneous coronary intervention in chronic statin users [Impacto na funcao renal de uma dose de reforco de rosuvastatina previa a intervencao coronaria percutanea eletiva nos pacientes em uso cronico de estatina]. Revista Brasileira de Cardiologia Invasiva 2012;20(3):303‐8. [EMBASE: 2013021434]
Han 2013 {published data only}
    1. Han S, Li XM, Mohammed Ali LA, Fu NK, Jin DX, Cong HL. Effect of short‐term different statins loading dose on renal function and CI‐AKI incidence in patients undergoing invasive coronary procedures. International Journal of Cardiology 2013;168(5):5101‐3. [MEDLINE: ] - PubMed
Liu 2013 {published data only}
    1. Liu WJ, Zhang BC, Guo R, Wei YD, Li WM, Xu YW. Renoprotective effect of alprostadil in combination with statins in patients with mild to moderate renal failure undergoing coronary angiography. Chinese Medical Journal 2013;126(18):3475‐80. [MEDLINE: ] - PubMed
NAPLES II Study 2009 {published data only}
    1. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, et al. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. Journal of the American College of Cardiology 2009;54(23):2157‐63. [MEDLINE: ] - PubMed
    1. Quintavalle C, Fiore D, Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast‐induced acute kidney injury. Circulation 2012;126(25):3008‐16. [MEDLINE: ] - PubMed
ROSA‐cIN Trial 2013 {published data only}
    1. Kaya A, Kurt M, Tanboga IH, Isik T, Ekinci M, Aksakal E, et al. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA‐cIN trial). Acta Cardiologica 2013;68(5):489‐94. [MEDLINE: ] - PubMed

References to ongoing studies

NCT01547455 {published data only}
    1. Zhou S. Anti‐inflammatory and renoprotective effect of pretreatment loading dose atorvastatin in CABG. www.clinicaltrials.gov/ct2/show/NCT01547455 (accessed 13 January 2015).
STATIN AKI 2011 {published data only}
    1. Billings FT 4th, Ball SK, Roberts LJ 2nd, Pretorius M. Postoperative acute kidney injury is associated with hemoglobinemia and an enhanced oxidative stress response. Free Radical Biology & Medicine 2011;50(11):1480‐7. [MEDLINE: ] - PMC - PubMed

Additional references

Ali 2005
    1. Ali IS, Buth KJ. Preoperative statin use and in‐hospital outcomes following heart surgery in patients with unstable angina. European Journal of Cardio‐Thoracic Surgery 2005;27(6):1051‐6. [MEDLINE: ] - PubMed
Arora 2008
    1. Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, et al. Preoperative use of angiotensin‐converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clinical Journal of the American Society of Nephrology: CJASN 2008;3(5):1266‐73. [MEDLINE: ] - PMC - PubMed
Asimakopoulos 2005
    1. Asimakopoulos G, Karagounis AP, Valencia O, Alexander N, Howlader M, Sarsam MA, et al. Renal function after cardiac surgery off‐ versus on‐pump coronary artery bypass: analysis using the Cockroft‐Gault formula for estimating creatinine clearance. Annals of Thoracic Surgery 2005;79(6):2024‐31. [MEDLINE: ] - PubMed
Baigent 2005
    1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol‐lowering treatment: prospective meta‐analysis of data from 90,056 participants in 14 randomised trials of statins. [Erratum appears in Lancet. 2008 Jun 21;371(9630):2084], [Erratum appears in Lancet. 2005 Oct 15‐21;366(9494):1358]. Lancet 2005;366(9493):1267‐78. [MEDLINE: ] - PubMed
Bellomo 2004
    1. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care 2004;8(4):R204‐12. [MEDLINE: ] - PMC - PubMed
Billings 2010
    1. Billings FT 4th, Pretorius M, Siew ED, Yu C, Brown NJ. Early postoperative statin therapy is associated with a lower incidence of acute kidney injury after cardiac surgery. Journal of Cardiothoracic & Vascular Anesthesia 2010;24(6):913‐20. [MEDLINE: ] - PMC - PubMed
Bove 2004
    1. Bove T, Calabrò MG, Landoni G, Aletti G, Marino G, Crescenzi G, et al. The incidence and risk of acute renal failure after cardiac surgery. Journal of Cardiothoracic & Vascular Anesthesia 2004;18(4):442‐5. [MEDLINE: ] - PubMed
Boyle 1997
    1. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Annals of Thoracic Surgery 1997;63(1):277‐84. [MEDLINE: ] - PubMed
Chawla 2012
    1. Chawla LS, Zhao Y, Lough FC, Schroeder E, Seneff MG, Brennan JM. Off‐pump versus on‐pump coronary artery bypass grafting outcomes stratified by preoperative renal function. Journal of the American Society of Nephrology 2012;23(8):1389‐97. [MEDLINE: ] - PMC - PubMed
Chertow 1997
    1. Chertow GM, Lazarus JM, Christiansen CL, Cook EF, Hammermeister KE, Grover F, et al. Preoperative renal risk stratification. Circulation 1997;95(4):878‐84. [MEDLINE: ] - PubMed
Chukwuemeka 2005
    1. Chukwuemeka A, Weisel A, Maganti M, Nette AF, Wijeysundera DN, Beattie WS, et al. Renal dysfunction in high‐risk patients after on‐pump and off‐pump coronary artery bypass surgery: a propensity score analysis. Annals of Thoracic Surgery 2005;80(6):2148‐53. [MEDLINE: ] - PubMed
Clark 2006
    1. Clark LL, Ikonomidis JS, Crawford FA Jr, Crumbley A 3rd, Kratz JM, Stroud MR, et al. Preoperative statin treatment is associated with reduced postoperative mortality and morbidity in patients undergoing cardiac surgery: an 8‐year retrospective cohort study. Journal of Thoracic & Cardiovascular Surgery 2006;131(3):679‐85. [MEDLINE: ] - PubMed
Coca 2009
    1. Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR. Long‐term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta‐analysis. American Journal of Kidney Diseases 2009;53(6):961‐73. [MEDLINE: ] - PMC - PubMed
Conlon 1999
    1. Conlon PJ, Stafford‐Smith M, White WD, Newman MF, King S, Winn MP, et al. Acute renal failure following cardiac surgery. Nephrology Dialysis Transplantation 1999;14(5):1158‐62. [MEDLINE: ] - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88. [MEDLINE: ] - PubMed
Devarajan 2006
    1. Devarajan P. Update on mechanisms of ischemic acute kidney injury. Journal of the American Society of Nephrology 2006;17(6):1503‐20. [MEDLINE: ] - PubMed
Egger 1997
    1. Egger M, Davey Smith G, Phillips AN. Meta‐analysis: Principles and procedures. BMJ 1997;315(7121):1533‐7. [MEDLINE: ] - PMC - PubMed
Endo 1976
    1. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase by ML‐236A and ML‐236B fungal metabolites, having hypocholesterolemic activity. FEBS Letters 1976;72(2):323‐6. [MEDLINE: ] - PubMed
Gueler 2002
    1. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, et al. Postischemic acute renal failure is reduced by short‐term statin treatment in a rat model. Journal of the American Society of Nephrology 2002;13(9):2288‐98. [MEDLINE: ] - PubMed
Haslinger‐Löffler 2008
    1. Haslinger‐Löffler B. Multiple effects of HMG‐CoA reductase inhibitors (statins) besides their lipid‐lowering function. Kidney International 2008;74(5):553‐5. [MEDLINE: ] - PubMed
Higgins 2003
    1. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. [MEDLINE: ] - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Inman 2005
    1. Inman SR, Davis NA, Mazzone ME, Olson KM, Lukaszek VA, Yoder KN. Simvastatin and L‐arginine preserve renal function after ischemia/reperfusion injury. American Journal of the Medical Sciences 2005;329(1):13‐7. [MEDLINE: ] - PubMed
Jo 2008
    1. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium‐induced nephropathy using short‐term high‐dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial‐‐a randomized controlled study. American Heart Journal 2008;155(3):499, e1‐8. [MEDLINE: ] - PubMed
Karkouti 2009
    1. Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, et al. Acute kidney injury after cardiac surgery: focus on modifiable risk factors. Circulation 2009;119(4):495‐502. [MEDLINE: ] - PubMed
Lafrance 2010
    1. Lafrance JP, Miller DR. Acute kidney injury associates with increased long‐term mortality. Journal of the American Society of Nephrology 2010;21(2):345‐52. [MEDLINE: ] - PMC - PubMed
Lamy 2012
    1. Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E, et al. Off‐pump or on‐pump coronary‐artery bypass grafting at 30 days. New England Journal of Medicine 2012;366(16):1489‐97. [MEDLINE: ] - PubMed
Li 2012
    1. Li Y, Liu Y, Fu L, Mei C, Dai B. Efficacy of short‐term high‐dose statin in preventing contrast‐induced nephropathy: a meta‐analysis of seven randomized controlled trials. PLoS One 2012;7(4):e34450. [MEDLINE: ] - PMC - PubMed
Liakopoulos 2008
    1. Liakopoulos OJ, Choi YH, Haldenwang PL, Strauch J, Wittwer T, Dörge H, et al. Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta‐analysis of over 30,000 patients. European Heart Journal 2008;29(12):1548‐59. [MEDLINE: ] - PubMed
Liakopoulos 2012
    1. Liakopoulos OJ, Kuhn EW, Slottosch I, Wassmer G, Wahlers T. Preoperative statin therapy for patients undergoing cardiac surgery. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD008493.pub2] - DOI - PubMed
Mangano 1998
    1. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Annals of Internal Medicine 1998;128(3):194‐203. [MEDLINE: ] - PubMed
Mariscalco 2011
    1. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A. Acute kidney injury: a relevant complication after cardiac surgery. Annals of Thoracic Surgery 2011;92(4):1539‐47. [MEDLINE: ] - PubMed
Mehta 2007
    1. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Critical Care 2007;11(2):R31. [MEDLINE: ] - PMC - PubMed
Mistiaen 2009
    1. Mistiaen W, Cauwelaert P, Muylaert P, Worm E. A thousand pericardial valves in aortic position: risk factors for postoperative acute renal function impairment in elderly. Journal of Cardiovascular Surgery 2009;50(2):233‐7. [MEDLINE: ] - PubMed
Morgan 2009
    1. Morgan C, Zappitelli M, Gill P. Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review. Critical Care 2009;13(5):R165. [MEDLINE: ] - PMC - PubMed
Ostermann 2000
    1. Ostermann ME, Taube D, Morgan CJ, Evans TW. Acute renal failure following cardiopulmonary bypass: a changing picture. Intensive Care Medicine 2000;26(5):565‐71. [MEDLINE: ] - PubMed
Ozan 2010
    1. Ozhan H, Erden I, Ordu S, Aydin M, Caglar O, Basar C, et al. Efficacy of short‐term high‐dose atorvastatin for prevention of contrast‐induced nephropathy in patients undergoing coronary angiography. Angiology 2010;61(7):711‐4. [MEDLINE: ] - PubMed
Pan 2004
    1. Pan W, Pintar T, Anton J, Lee VV, Vaughn WK, Collard CD. Statins are associated with a reduced incidence of perioperative mortality after coronary artery bypass graft surgery. Circulation 2004;110(11 Suppl 1):II45‐9. [MEDLINE: ] - PubMed
Patti 2008
    1. Patti G. Short‐term high‐dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction. Journal of Cardiovascular Medicine 2011;12(5):305‐8. [MEDLINE: ] - PubMed
Srisawat 2010
    1. Srisawat N, Lawsin L, Uchino S, Bellomo R, Kellum JA, BEST Kidney Investigators. Cost of acute renal replacement therapy in the intensive care unit: results from The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) study. Critical Care 2010;14(2):R46. [MEDLINE: ] - PMC - PubMed
Sterne 2001
    1. Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta‐analysis. BMJ 2001;327(7304):101‐5. [MEDLINE: ] - PMC - PubMed
Swaminathan 2007
    1. Swaminathan M, Shaw AD, Phillips‐Bute BG, McGugan‐Clark PL, Archer LE, Talbert S, et al. Trends in acute renal failure associated with coronary artery bypass graft surgery in the United States. Critical Care Medicine 2007;35(10):2286‐91. [MEDLINE: ] - PubMed
Tabata 2007
    1. Tabata M, Khalpey Z, Pirundini PA, Byrne ML, Cohn LH, Rawn JD. Renoprotective effect of preoperative statins in coronary artery bypass grafting. American Journal of Cardiology 2007;100(3):442‐4. [MEDLINE: ] - PubMed
Thakar 2003
    1. Thakar CV, Liangos O, Yared JP, Nelson D, Piedmonte MR, Hariachar S, et al. ARF after open‐heart surgery: Influence of gender and race. American Journal of Kidney Diseases 2003;41(4):742‐51. [MEDLINE: ] - PubMed
Yokota 2003
    1. Yokota N, O'Donnell M, Daniels F, Burne‐Taney M, Keane W, Kasiske B, et al. Protective effect of HMG‐CoA reductase inhibitor on experimental renal ischemia‐reperfusion injury. American Journal of Nephrology 2003;23(1):13‐7. [MEDLINE: ] - PubMed

References to other published versions of this review

Lewicki 2013
    1. Lewicki M, Ng I, Schneider AG. HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD010480] - DOI - PMC - PubMed

MeSH terms